2), metastatic site, and second-line treatment in sufferers withKRASwild-type vs
2), metastatic site, and second-line treatment in sufferers withKRASwild-type vs.KRASmutant samples. types. == Outcomes == PNA-PCR was a lot more delicate in detectingKRASmutations than sequencing (41% vs. 30%, p <…